FibroBiologics Announces 2025 Annual Meeting of Stockholders
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotechnology company, has announced its 2025 Annual Meeting of Stockholders, scheduled for June 12, 2025, at 11 a.m. CDT. The meeting will be held exclusively in a virtual format.
The company, which focuses on developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, has set April 14, 2025 as the record date for stockholder voting eligibility. FibroBiologics currently maintains a portfolio of 160+ US and international patents/patents pending across various clinical pathways, including:
- Disc degeneration
- Orthopedics
- Multiple sclerosis
- Psoriasis
- Wound healing
- Reversing organ involution
- Cancer
FibroBiologics (Nasdaq: FBLG), un'azienda biotecnologica in fase clinica, ha annunciato la sua Assemblea Annuale degli Azionisti 2025, prevista per 12 giugno 2025, alle 11:00 CDT. L'incontro si svolgerà esclusivamente in formato virtuale.
L'azienda, che si concentra sullo sviluppo di terapie e potenziali cure per malattie croniche utilizzando fibroblasti e materiali derivati dai fibroblasti, ha fissato 14 aprile 2025 come data di registrazione per l'idoneità al voto degli azionisti. FibroBiologics attualmente mantiene un portafoglio di oltre 160 brevetti statunitensi e internazionali/brevetti in attesa in vari percorsi clinici, tra cui:
- Degenerazione del disco
- Ortopedia
- Sclerosi multipla
- Psoriasi
- Cicatrizzazione delle ferite
- Inversione dell'involuzione degli organi
- Cancro
FibroBiologics (Nasdaq: FBLG), una empresa biotecnológica en etapa clínica, ha anunciado su Junta Anual de Accionistas 2025, programada para 12 de junio de 2025, a las 11 a.m. CDT. La reunión se llevará a cabo exclusivamente en formato virtual.
La empresa, que se centra en el desarrollo de terapias y posibles curas para enfermedades crónicas utilizando fibroblastos y materiales derivados de fibroblastos, ha establecido el 14 de abril de 2025 como la fecha de registro para la elegibilidad de voto de los accionistas. FibroBiologics actualmente mantiene un portafolio de más de 160 patentes estadounidenses e internacionales/patentes pendientes en varios caminos clínicos, incluidos:
- Degeneración del disco
- Ortopedia
- Psoriasis
- Cicatrización de heridas
- Inversión de la involución de órganos
- Cáncer
FibroBiologics (Nasdaq: FBLG), 임상 단계의 생명공학 회사가 2025년 6월 12일 오전 11시 CDT에 예정된 2025년 주주 총회를 발표했습니다. 회의는 전적으로 가상 형식으로 진행됩니다.
이 회사는 섬유아세포 및 섬유아세포 유래 물질을 사용하여 만성 질환에 대한 치료제 및 잠재적 치료법을 개발하는 데 주력하고 있으며, 2025년 4월 14일을 주주 투표 자격 등록일로 설정했습니다. FibroBiologics는 현재 160개 이상의 미국 및 국제 특허/출원 중인 특허를 다양한 임상 경로에서 보유하고 있습니다. 포함된 내용은:
- 디스크 퇴행
- 정형외과
- 다발성 경화증
- 건선
- 상처 치유
- 장기 퇴화 역전
- 암
FibroBiologics (Nasdaq: FBLG), une entreprise de biotechnologie en phase clinique, a annoncé sa Réunion Annuelle des Actionnaires 2025, prévue pour le 12 juin 2025 à 11h00 CDT. La réunion se déroulera exclusivement en format virtuel.
L'entreprise, qui se concentre sur le développement de thérapies et de traitements potentiels pour les maladies chroniques en utilisant des fibroblastes et des matériaux dérivés de fibroblastes, a fixé le 14 avril 2025 comme date d'enregistrement pour l'éligibilité au vote des actionnaires. FibroBiologics possède actuellement un portefeuille de plus de 160 brevets américains et internationaux/brevets en attente dans divers domaines cliniques, notamment :
- Dégénérescence discale
- Orthopédie
- Sclérose en plaques
- Psoriasis
- Cicatrisation des plaies
- Inversion de l'involution des organes
- Cancer
FibroBiologics (Nasdaq: FBLG), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat seine Jahreshauptversammlung der Aktionäre 2025 angekündigt, die für 12. Juni 2025, um 11 Uhr CDT angesetzt ist. Die Sitzung findet ausschließlich in virtueller Form statt.
Das Unternehmen, das sich auf die Entwicklung von Therapeutika und potenziellen Heilungen für chronische Krankheiten mit Fibroblasten und aus Fibroblasten gewonnenen Materialien konzentriert, hat 14. April 2025 als Stichtag für die Stimmberechtigung der Aktionäre festgelegt. FibroBiologics hält derzeit ein Portfolio von über 160 US- und internationalen Patenten/Patentanmeldungen in verschiedenen klinischen Bereichen, darunter:
- Diskdegeneration
- Orthopädie
- Multiple Sklerose
- Psoriasis
- Wundheilung
- Umkehrung der Organinvolution
- Krebs
- Portfolio of 160+ US and international patents/patents pending across multiple therapeutic areas
- None.
HOUSTON, March 27, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that its 2025 Annual Meeting of Stockholders will take place on June 12, 2025, at 11 a.m. CDT, exclusively through a virtual format. The record date for determination of stockholders entitled to vote at the annual meeting is April 14, 2025.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
FAQ
When is FibroBiologics (FBLG) 2025 Annual Stockholders Meeting?
What is the record date for voting eligibility at FBLG's 2025 Annual Meeting?
How many patents does FibroBiologics (FBLG) currently hold?
What medical conditions is FibroBiologics (FBLG) developing treatments for?
